CD278 explained
Inducible T-cell costimulator (also called CD278) is an immune checkpoint protein that in humans is encoded by the ICOS (Inducible T-cell COStimulator) gene.[1] [2] [3] [4] [5] The protein belongs to the CD28 and CTLA-4 cell-surface receptor family. These are proteins expressed on the surface of immune cells that mediate signalling between them. A surface protein, the ligand, binds specifically to its receptor on another cell, leading to a signalling cascade in that cell.
Function
ICOS is a receptor protein expressed on the surface of activated T cells. Its ligand ICOS-L (previously called B7RP-1) is constitutively expressed on B cells. Stimulation of the ICOS receptor on T cells by ICOS-L on B cells is required for the development of follicular helper T (Tfh) cells.[6] ICOS forms homodimers and plays an important role in cell-cell signaling, immune responses and regulation of cell proliferation.[3]
Knockout phenotype
Compared to wild-type naïve T cells, ICOS-/- T cells activated with plate-bound anti-CD3 have reduced proliferation and IL-2 secretion.[7] The defect in proliferation can be rescued by addition of IL-2 to the culture, suggesting the proliferative defect is due either to ICOS-mediated IL-2 secretion or the activation of similar signaling pathways between ICOS and IL-2. In terms of Th1 and Th2 cytokine secretion, ICOS-/- CD4+ T cell activated in vitro reduced IL-4 secretion, while maintaining similar IFN-g secretion. Similarly, CD4+ T cells purified from ICOS-/- mice immunized with the protein keyhole limpet hemocyanin (KLH) in alum or complete Freund's Adjuvant have attenuated IL-4 secretion, but similar IFN-g and IL-5 secretion when recalled with KLH.
These data are similar to an airway hypersensitivity model showing similar IL-5 secretion, but reduced IL-4 secretion in response to sensitization with Ova protein, indicating a defect in Th2 cytokine secretion, but not a defect in Th1 differentiation as both IL-4 and IL-5 are Th2-associated cytokines. In agreement with reduced Th2 responses, ICOS-/- mice expressed reduced germinal center formation and IgG1 and IgE antibody titers in response to immunization.
Combination therapy
Ipilimumab patients expressed increased ICOS+ T cells in tumor tissues and blood. The increase served as a pharmacodynamic biomarker of anti-CTLA-4 treatment. In wild-type C57BL/6 mice, anti-CTLA-4 treatment resulted in tumor rejection in 80 to 90% of subjects, but in gene-targeted mice that were deficient for either ICOS or its ligand (ICOSLG), the efficacy was less than 50%. An agonistic stimulus for the ICOS pathway during anti-CTLA-4 therapy resulted in an increase in efficacy that was about four to five times as large as that of control treatments. This combination therapy incorporating ICOS costimulation and CTLA-4 blockade effectively remodels tumor-associated macrophages (TAMs) towards an antitumor phenotype, demonstrating promising therapeutic potential in cancer treatment.[8] As of 2015 antibodies for ICOS were not available for clinical testing.[9]
Further reading
- Flesch IE . Inducible costimulator (ICOS) . Journal of Biological Regulators and Homeostatic Agents . 16 . 3 . 214–6 . 2003 . 12456021 .
- Shilling RA, Bandukwala HS, Sperling AI . Regulation of T:B cell interactions by the inducible costimulator molecule: does ICOS "induce" disease? . Clinical Immunology . 121 . 1 . 13–8 . Oct 2006 . 16790364 . 10.1016/j.clim.2006.04.574 .
- Ling V, Wu PW, Finnerty HF, Bean KM, Spaulding V, Fouser LA, Leonard JP, Hunter SE, Zollner R, Thomas JL, Miyashiro JS, Jacobs KA, Collins M . Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor . Journal of Immunology . 164 . 4 . 1653–7 . Feb 2000 . 10657606 . 10.4049/jimmunol.164.4.1653 . free .
- Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D, Buckwalter S, Ledbetter JA, Clark EA . Characterization of human inducible costimulator ligand expression and function . Journal of Immunology . 164 . 9 . 4689–96 . May 2000 . 10779774 . 10.4049/jimmunol.164.9.4689 . free .
- Machado RD, Pauciulo MW, Fretwell N, Veal C, Thomson JR, Vilariño Güell C, Aldred M, Brannon CA, Trembath RC, Nichols WC . A physical and transcript map based upon refinement of the critical interval for PPH1, a gene for familial primary pulmonary hypertension. The International PPH Consortium . Genomics . 68 . 2 . 220–8 . Sep 2000 . 10964520 . 10.1006/geno.2000.6291 .
- Tezuka K, Tsuji T, Hirano D, Tamatani T, Sakamaki K, Kobayashi Y, Kamada M . Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family . Biochemical and Biophysical Research Communications . 276 . 1 . 335–45 . Sep 2000 . 11006126 . 10.1006/bbrc.2000.3466 .
- Wang S, Zhu G, Chapoval AI, Dong H, Tamada K, Ni J, Chen L . Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS . Blood . 96 . 8 . 2808–13 . Oct 2000 . 11023515 . 10.1182/blood.V96.8.2808.
- Breitfeld D, Ohl L, Kremmer E, Ellwart J, Sallusto F, Lipp M, Förster R . Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production . The Journal of Experimental Medicine . 192 . 11 . 1545–52 . Dec 2000 . 11104797 . 2193094 . 10.1084/jem.192.11.1545 .
- Beier KC, Hutloff A, Dittrich AM, Heuck C, Rauch A, Büchner K, Ludewig B, Ochs HD, Mages HW, Kroczek RA . Induction, binding specificity and function of human ICOS . European Journal of Immunology . 30 . 12 . 3707–17 . Dec 2000 . 11169414 . 10.1002/1521-4141(200012)30:12<3707::AID-IMMU3707>3.0.CO;2-Q . free .
- Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, Chen S, Jussiff JM, Fisk GJ, Miller CP, Collins M . Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches . Genomics . 78 . 3 . 155–68 . Dec 2001 . 11735222 . 10.1006/geno.2001.6655 .
- Lee YH, Ji JD, Sohn J, Song GG . Polymorphsims of CTLA-4 exon 1 +49, CTLA-4 promoter -318 and Fas promoter -670 in spondyloarthropathies . Clinical Rheumatology . 20 . 6 . 420–2 . 2002 . 11771526 . 10.1007/s100670170007 . 21094500 .
- Haimila KE, Partanen JA, Holopainen PM . Genetic polymorphism of the human ICOS gene . Immunogenetics . 53 . 12 . 1028–32 . Mar 2002 . 11904679 . 10.1007/s00251-002-0431-2 . 2721092 .
- Wang S, Zhu G, Tamada K, Chen L, Bajorath J . Ligand binding sites of inducible costimulator and high avidity mutants with improved function . The Journal of Experimental Medicine . 195 . 8 . 1033–41 . Apr 2002 . 11956294 . 2193694 . 10.1084/jem.20011607 .
- Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson BP, June CH, Linsley PS . Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors . Proceedings of the National Academy of Sciences of the United States of America . 99 . 18 . 11790–5 . Sep 2002 . 12195015 . 129347 . 10.1073/pnas.162359999 . 2002PNAS...9911790R . free .
- Witsch EJ, Peiser M, Hutloff A, Büchner K, Dorner BG, Jonuleit H, Mages HW, Kroczek RA . ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells . European Journal of Immunology . 32 . 9 . 2680–6 . Sep 2002 . 12207353 . 10.1002/1521-4141(200209)32:9<2680::AID-IMMU2680>3.0.CO;2-6 . free .
- Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA . Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences . Proceedings of the National Academy of Sciences of the United States of America . 99 . 26 . 16899–903 . Dec 2002 . 12477932 . 139241 . 10.1073/pnas.242603899 . 2002PNAS...9916899M . free .
- Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Dräger R, Eibel H, Fischer B, Schäffer AA, Mages HW, Kroczek RA, Peter HH . Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency . Nature Immunology . 4 . 3 . 261–8 . Mar 2003 . 12577056 . 10.1038/ni902 . 20069932 .
Notes and References
- Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA . ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 . Nature . 397 . 6716 . 263–6 . Jan 1999 . 9930702 . 10.1038/16717 . 1999Natur.397..263H . 4415254 .
- Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L, Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G . T-cell co-stimulation through B7RP-1 and ICOS . Nature . 402 . 6763 . 827–32 . Dec 1999 . 10617205 . 10.1038/45582 . 1999Natur.402..827Y . 4360410 .
- Web site: Entrez Gene: ICOS inducible T-cell co-stimulator.
- Rudd CE, Schneider H . Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling . Nature Reviews. Immunology . 3 . 7 . 544–56 . Jul 2003 . 12876557 . 10.1038/nri1131 . 19833513 .
- Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA . ICOS co-stimulatory receptor is essential for T-cell activation and function . Nature . 409 . 6816 . 97–101 . Jan 2001 . 11343121 . 10.1038/35051100 . 2001Natur.409...97D . 11891841 .
- Akiba . Hisaya . The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo . The Journal of Immunology . 2005 . 175 . 4 . 2340–2348 . 10.4049/jimmunol.175.4.2340 . 16081804 .
- Book: Stefan . Dübel . Janice M. . Reichert. Handbook of Therapeutic Antibodies . 2014 . Wiley-VCH . Weinheim, Bergstr . 978-3-527-32937-3 . 1088–9 . 2 . https://books.google.com/books?id=I9k8BAAAQBAJ&q=ICOS+IL-2+CD3++Th1+Th2&pg=PA1088 . Frank R. . Brennan . T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders .
- Sharma N, Fan X, Atolagbe OT, Ge Z, Dao KN, Sharma P, Allison JP . ICOS costimulation in combination with CTLA-4 blockade remodels tumor-associated macrophages toward an antitumor phenotype. The Journal of Experimental Medicine . 221 . 4 . April 2024 . 38517331 . 10959121 . 10.1084/jem.20231263 .
- Sharma P, Allison JP . The future of immune checkpoint therapy . Science . 348 . 6230 . 56–61 . Apr 2015 . 25838373 . 10.1126/science.aaa8172 . 2015Sci...348...56S . 4608450 .